Written By: Pharmacally Medical News Desk
Sun Pharma has launched its global innovative biologic drug, Ilumya® (tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis. This launch is expanding Sun Pharma’s global specialty portfolio and providing advanced treatment options to Indian patients struggling with this chronic skin condition. Ilumya® is a novel biologic therapy that selectively targets and inhibits interleukin-23 (IL-23), a key driver of inflammation in psoriasis, offering long-lasting skin clearance and a strong safety profile with minimal monitoring requirements.
Ilumya® was originally launched in the US about six years ago and is now available in over 35 countries worldwide. The drug has demonstrated robust efficacy and safety in clinical studies, including a dedicated Indian Phase-3 trial with 115 patients. This trial showed impressive results with 93.9% of patients achieving at least a 75% reduction in the Psoriasis Area Severity Index (PASI 75) by week 28, and 78.1% achieving near-complete clearance (PASI 90). The therapy’s dosing schedule of just five injections per year enhances convenience and adherence for patients.
Sun Pharma’s Managing Director, Kirti Ganorkar, emphasizes that Ilumya® offers a safe and effective treatment option for moderate-to-severe plaque psoriasis in India, aligning with the company’s mission to bring its global innovative medicines to the domestic market. This launch also strengthens Sun Pharma’s specialty medicines segment, which reported strong sales growth fueled by key innovative products. Ilumya® is a promising advancement for improving the quality of life for psoriasis patients in India by providing targeted and durable disease control.
Key Highlights of Ilumya®:
- Biologic treatment targeting IL-23 to inhibit psoriasis inflammation
- Indicated for moderate-to-severe plaque psoriasis in adults
- Approved and used globally in 35+ countries including the US
- Demonstrated high PASI 75 and PASI 90 response rates in Indian Phase-3 clinical trial
- Convenient dosing: subcutaneous injections at weeks 0, 4, and every 12 weeks thereafter
- Strong safety profile with minimal monitoring burden
This launch gives Indian patients access to an internationally recognized, innovative dermatology treatment backed by Sun Pharma’s comprehensive clinical research and global expertise, reaffirming the company’s leadership in specialty pharmaceuticals.
References
Sun Pharma introduces its global innovative drug, Ilumya® in India for treatment of moderate-to-severe Plaque Psoriasis, 01 December 2025, Sun Pharmaceuticals, https://sunpharma.com/wp-content/uploads/2025/12/Press-Release-Sun-Pharma-introduces-it-global-innovative-drug-Ilumya-in-India.pdf